Reimbursement recommendation


Colin Kerr
Published: Saturday, February 1, 2020
Santen Canada Inc., a subsidiary of Santen Pharmaceutical Co., Ltd. has announced that the Canadian Agency for Drugs and Technologies in Health Canadian Drug Expert Committee released a reimbursement recommendation for Verkazia TM (cyclosporine 0.1%) eyedrops.
“This recommendation marks an important step towards providing patients access to this new formulation of cyclosporine eye drops in Canada. Provincial jurisdictions are the final decision makers on public reimbursement,” said a Santen spokeswoman.
www.santen.com
Tags: industry, santen
Latest Articles
ESCRS Today 2025: Happy Anniversaries!
ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.
ESCRS Today 2025: A Congress for Everyone
From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Debate: FS-LASIK or KLEx for Hyperopia?
FS-LASIK has more of a track record, but KLEx offers advantages.
Four AI Applications Ready for Practice
Commercial offerings may save time, improve practice and research.
Perioperative Medication Regimens for Cataract Surgery
Randomised controlled clinical trial results provide evidence-based guidance.